Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Low-Toxicity Anticancer Agent Proves Effective Against a Variety of Cancers

By BiotechDaily International staff writers
Posted on 08 Apr 2013
Researchers have discovered that the small chemical molecule FL118, a new formulation of a promising anticancer agent, is even more effective in controlling two kinds of cancer than an older version of the compound proved to be six months earlier. Further findings also suggest that the agent may successfully treat other solid tumors as well.

In their earlier research, a team led by Fengzhi Li, PhD, associate professor of oncology in Roswell Park Cancer Institute’s (RPCI; Buffalo, NY, USA) department of pharmacology and therapeutics, demonstrated that FL118 eliminated human colon and head-and-neck tumors in animal models without relapse but was limited in that it could be delivered only by intraperitoneal (IP) administration. This new study, to be published in the April 8, 2013, issue of the American Journal of Translational Research, compares the earlier formulation of the agent to a new version that can also be administered intravenously, adapting it to a much wider potential clinical application.

Comparing the antitumor effectiveness and therapeutic index, or relative toxicity, of FL118 in its new intravenous (IV) formulation with the earlier form, the researchers found that maximum tolerated dose increased three- to seven-fold, depending on dosing regimen. While the original formulation contained Tween 80 or polysorbate 80, a solvent typically included in drug formulations, the agent in its new composition is free of Tween 80, resulting in significantly lower toxicity.

FL118 is a targeted therapy that selectively inhibits the expression of four major cancer-survival gene products: survivin, XIAP, Mcl-1, and/or cIAP2. Whereas both studies assessed the compound’s effectiveness against models of head-and-neck and colon tumors, other research from Dr. Li’s lab suggests that mesothelioma, ovarian, and pancreatic cancers, and potentially other solid tumors, may also be good targets for treatment with FL118.

“This work represents a significant move forward,” noted Dr. Li, senior author on the study. “We’re targeting four of the most resilient and pervasive cancer survival mechanisms, and because the findings from preclinical testing have been so striking, we’re anxious to see FL118 tested in the clinical setting.”

The study’s findings were published online April 2, 2013, in the journal PLOS ONE.

Related Links:

Roswell Park Cancer Institute



view channel
Image: Schematic representation of HIV DART binding to two distinct antigens simultaneously, redirecting the killer T-cells to destroy HIV-1 infected cells (Photo courtesy of Duke University).

Bi-Specific Antibodies Shown to Clear Latent HIV Infections

Bi-specific antibodies or DARTS (dual-affinity re-targeting proteins) have been used to eliminate latent HIV-infection from patient samples by redirecting polyclonal T-cells to specifically engage with... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


view channel

Sale of Mexican Pharmaceutical Company Expected to Boost Latin American Prescription Drug Market

The sale of a major Mexican pharmaceutical company to an international generic drug corporation is expected to accelerate the growth of the Latin American market for prescription drugs. Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel) announced that it has entered into definitive agreements to buy Representaciones... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.